{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:31:45Z","timestamp":1791811905118,"version":"4.3.4"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A network meta-analysis of randomized controlled trials (RCTs) was conducted to explore the cardiovascular outcomes of all the kind and dosages of sodium-glucose cotransport-2 (SGLT2) inhibitors in type 2 diabetes mellitus (T2DM) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method and Result<\/jats:title><jats:p>The Cochrane Library, PubMed, and Embase databases were systematically searched for studies to compare the therapeutic effects of different SGLT2 inhibitors in T2DM patients. The effect measurements estimate chosen were odds ratios (ORs) and their corresponding 95% confidence interval (CI). Forty-seven RCTs involving a total of 70574 participants were eligible for direct and indirect comparisons. In direct comparison, treatment with dapagliflozin 5mg showed significantly lower risk of all-cause mortality compared with treatment with dapagliflozin 2.5mg (OR 0.09, 95% CI 0.01-0.70). According to NMA, interestingly, empagliflozin 10mg\/25mg, and canagliflozin 100mg was associated with significantly lower risks of all-cause mortality compared with placebo (OR of 0.70, 95% CI 0.58-0.85; 0.69, 95% CI 0.57-0.84; and 0.83, 95% CI 0.73-0.95, respectively). Compared with placebo, dapagliflozin 10mg, empagliflozin 10mg and 25mg displayed the lower risks for cardiovascular events (OR 0.78, 95% CI 0.44-1.00; OR 0.47, 95% CI 0.22-0.93; and 0.43, 95% CI 0.24-0.74, respectively) by direct comparison. Moreover, canagliflozin 100\/300mg showed significantly higher risks of cardiovascular events compared with empagliflozin 10mg (OR of 4.83, 95% CI 1.14-20.46 and 5.31, 95% CI 1.26-22.34, respectively) and empagliflozin 25mg (4.23, 95% CI 1.13-15.83 and 4.65, 95% CI 1.25-17.27, respectively) according to NMA. There were non-significant differences among all interventions in volume depletion in traditional pairwise meta-analysis. While in NMA, canagliflozin 100\/300mg were associated with significantly increased risks of volume depletion compared with placebo (OR of 1.47, 95% CI 1.08-1.99 and 2.19, 95% CI 1.66-2.90, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the limitations of the NMA, this study showed that empagliflozin might be better than other SGLT2 inhibitors with low risks of all-cause mortality and cardiovascular events in patients with T2DM suggesting the need for <jats:italic>ad hoc<\/jats:italic> RCTs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.802992","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:21:10Z","timestamp":1647433270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Yu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global Estimates of Diabetes Prevalence for 2017 and Projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of Cardiovascular Disease in Type 2 Diabetes: A Systematic Literature Review of Scientific Evidence From Across the World in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of Cardiometabolic Multimorbidity With Mortality","volume":"314","author":"Emerging Risk Factors","year":"2015","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3315","article-title":"Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes: The GIPS-III Randomized Clinical Trial","volume":"311","author":"Lexis","year":"2014","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ejhf.633","article-title":"Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients With Diabetes","volume":"19","author":"Fitchett","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2015.39.5.373","article-title":"Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients With Type 2 Diabetes: A Tale of Three Studies","volume":"39","author":"Son","year":"2015","journal-title":"Diabetes Metab J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its Effects on Hyperglycaemia and Albuminuria in Patients With Type 2 Diabetes and Renal Dysfunction: The Randomized MARLINA-T2D Trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a Therapeutic Target for Diabetes: Basic Physiology and Consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0029","article-title":"Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The Effect of Empagliflozin on Arterial Stiffness and Heart Rate Variability in Subjects With Uncomplicated Type 1 Diabetes Mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1312","article-title":"Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care Dec"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875","article-title":"Combination of Direct and Indirect Evidence in Mixed Treatment Comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Internal Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10618600.1998.10474787","article-title":"General Methods for Monitoring Convergence of Iterative Simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical Methods and Numerical Summaries for Presenting Results From Multiple-Treatment Meta-Analysis: An Overview and Tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian Measures of Model Complexity and Fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc: Ser b (Stat Methodol)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin Add-on to Metformin in Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized, Double-Blind, Placebo-Controlled 102-Week Trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12624","article-title":"Efficacy and Safety of Dapagliflozin Monotherapy in People With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled 102-Week Trial","volume":"32","author":"Bailey","year":"2015","journal-title":"Diabetic Med J Br Diabetic Assoc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and Safety of Empagliflozin Added to Existing Antidiabetes Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-Term Efficacy and Safety of Canagliflozin Over 104 Weeks in Patients Aged 55-80 Years With Type 2 Diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12933-017-0517-7","article-title":"Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Based on History of Cardiovascular Disease or Cardiovascular Risk Factors: A Post Hoc Analysis of Pooled Data","volume":"16","author":"Davies","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-236","article-title":"Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13413","article-title":"Efficacy and Safety of Dapagliflozin in Patients With Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12081","article-title":"A Phase IIb, Randomized, Placebo-Controlled Study of the SGLT2 Inhibitor Empagliflozin in Patients With Type 2 Diabetes","volume":"15","author":"Ferrannini","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy (DURATION-8): A 28 Week, Multicentre, Double-Blind, Phase 3, Randomised Controlled Trial","volume":"4","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/dom.12589","article-title":"Efficacy and Safety of Canagliflozin When Used in Conjunction With Incretin-Mimetic Therapy in Patients With Type 2 Diabetes","volume":"18","author":"Fulcher","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/dom.12589","article-title":"Empagliflozin as Add-on to Metformin Plus Sulphonylurea in Patients With Type 2 Diabetes","volume":"110","author":"Haering","year":"2015","journal-title":"Diabetes Res Clin Practice"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0052","article-title":"Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients With Type 2 Diabetes: A Randomized Controlled Trial","volume":"20","author":"Henry","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","article-title":"Efficacy and Safety of Canagliflozin in Combination With Insulin: A Double-Blind, Randomized, Placebo-Controlled Study in Japanese Patients With Type 2 Diabetes Mellitus","volume":"15","author":"Inagaki","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0680","article-title":"Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial","volume":"41","author":"Jabbour","year":"2018","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Adv Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12325","article-title":"Efficacy and Safety of Dapagliflozin Monotherapy in Japanese Patients With Type 2 Diabetes Inadequately Controlled by Diet and Exercise","volume":"16","author":"Kaku","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12325","article-title":"Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease- Results From EMPA-REG OUTCOME((R))","volume":"81","author":"Kaku","year":"2017","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356","article-title":"Long-Term Study of Patients With Type 2 Diabetes and Moderate Renal Impairment Shows That Dapagliflozin Reduces Weight and Blood Pressure But Does Not Improve Glycemic Control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as Add-On Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus","volume":"37","author":"Kovacs","year":"2015","journal-title":"Clin Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1121865","article-title":"Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus From Latin America","volume":"32","author":"Lavalle-Gonzalez","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1121865","article-title":"Dapagliflozin Added to Usual Care in Individuals With Type 2 Diabetes Mellitus With Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1391759","article-title":"Achieving the Composite Endpoint of HbA1c, Body Weight, and Systolic Blood Pressure Reduction With Canagliflozin in Patients With Type 2 Diabetes","volume":"34","author":"Merton","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, Tolerability and Effects on Cardiometabolic Risk Factors of Empagliflozin Monotherapy in Drug-Naive Patients With Type 2 Diabetes: A Double-Blind Extension of a Phase III Randomized Controlled Trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.07.016","article-title":"Empagliflozin in Combination With Oral Agents in Young and Overweight\/Obese Type 2 Diabetes Mellitus Patients: A Pooled Analysis of Three Randomized Trials","volume":"30","author":"Romera","year":"2016","journal-title":"J Diabetes Complications"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1736","article-title":"Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12185","article-title":"Efficacy and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, as Add-on to Metformin in Type 2 Diabetes With Mild Hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12503","article-title":"Impact of Empagliflozin Added on to Basal Insulin in Type 2 Diabetes Inadequately Controlled on Basal Insulin: A 78-Week Randomized, Double-Blind, Placebo-Controlled Trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.12387","article-title":"Twice-Daily Dapagliflozin Co-Administered With Metformin in Type 2 Diabetes: A 16-Week Randomized, Placebo-Controlled Clinical Trial","volume":"17","author":"Schumm-Draeger","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older With Type 2 Diabetes Mellitus: A Pooled Analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial","volume":"40","author":"Softeland","year":"2017","journal-title":"Diabetes Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-Term Efficacy and Safety of Canagliflozin Monotherapy in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise: Findings From the 52-Week CANTATA-M Study","volume":"30","author":"Stenlof","year":"2014","journal-title":"Curr Med Res Opinion"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0072-0","article-title":"Dapagliflozin Added to Glimepiride in Patients With Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial","volume":"5","author":"Strojek","year":"2014","journal-title":"Diabetes Ther Res Treat Educ Diabetes Rel Disord"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096","article-title":"Linagliptin as Add-on to Empagliflozin and Metformin in Patients With Type 2 Diabetes: Two 24-Week Randomized, Double-Blind, Double-Dummy, Parallel-Group Trials","volume":"19","author":"Tinahones","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood Pressure and Glycaemic Effects of Dapagliflozin Versus Placebo in Patients With Type 2 Diabetes on Combination Antihypertensive Therapy: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Sulphonylurea: A Randomised Trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12348","article-title":"Efficacy and Safety of Canagliflozin Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1016\/j.clinthera.2017.10.003","article-title":"Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus","volume":"39","author":"Yale","year":"2017","journal-title":"Clin Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5A0717-302","article-title":"A Novel Function of CXCL10 in Mediating Monocyte Production of Proinflammatory Cytokines","volume":"102","author":"Zhao","year":"2017","journal-title":"J Leukocyte Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12634","article-title":"Dapagliflozin as Add-on Therapy in Asian Patients With Type 2 Diabetes Inadequately Controlled on Insulin With or Without Oral Antihyperglycemic Drugs: A Randomized Controlled Trial","volume":"10","author":"Yang","year":"2018","journal-title":"J Diabetes"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"107590","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Effect of Dapagliflozin on Cardiac Function in People With Type 2 Diabetes and Albuminuria - A Double Blind Randomized Placebo-Controlled Crossover Trial","volume":"34","author":"Eickhoff","year":"2020","journal-title":"J Diabetes Complications"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3024","article-title":"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"Jama"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic Differences Between Canagliflozin and Dapagliflozin: Results of a Randomized, Double-Blind, Crossover Study","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0058","article-title":"The Na+\/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a Glucose-Regulating Drug With Diuretic Properties in Subjects With Type 2 Diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.802992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:21:14Z","timestamp":1647433274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.802992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":71,"alternative-id":["10.3389\/fendo.2022.802992"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.802992","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"article-number":"802992"}}